Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kernel has launched the second generation of its wearable neuroimaging device ("Flow2"), which is being used in observational studies to identify biomarkers for depression treatment response and cognitive decline. The technology is validated through multiple peer-reviewed publications. Early clinical results show promise in enabling patient-specific biomarker development for neuromedicine applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kernel.